Most of us use
Empower Pharmacy. They have great customer service and are registered in all states. Jasen Bruce and myself have joined forces with
Shaun Noorian to make Empower the best in the field.
Interview with Compounding Product Expert Shaun Noorian from Empower Rx Pharmacy- Part 1
Due to their brand new state-of-the-art 15,000 sq ft manufacturing facility,
Empower Pharmacy will soon be one of the few remaining compounding pharmacies allowed to manufacture sterile injectable products that meet new FDA regulations under the 503B outsourcing registration. As a 503B registered pharmacy,
Empower Pharmacy has been approved by the FDA to manufacture custom injectable, oral, topical and subcutaneous medications in large quantities to ship directly to clinics and hospitals. They can also compound patient-specific medications that can be customized for the patient to self-administer. Being able to manufacture larger quantities is one reason Empower is able to offer their catalog of medications at a very low price.
Empower Pharmacy is one of the few facilities licensed in all 50 states to provide both patient-specific and bulk medications for clinic administration. To maintain good FDA standing,
Empower Pharmacy adheres to current Good Manufacturing Practices (cGMP) and United States Pharmacopeia (USP) guidelines. The following short video will provide a quick introduction and visual tour of the pharmacy:
Empower Pharmacy Video Introduction
As mentioned before, the FDA has been updating the regulations that govern all compounding pharmacies in order to create a strict standard for how sterile and non-sterile medications should be compounded. Regarding the compounding of sterile medications, the FDA has made it a requirement for 503B facilities to test every single batch of a sterile compound at a FDA approved analytical laboratory for potency, sterility, and endotoxin content. This requirement ensures that the medication remains stable and sterile over time.
Unfortunately, these new FDA regulations have significantly increased the cost and complexity of compounding which will result in the closure of many compounding pharmacies currently in business (most are registered as 503A community based compounding pharmacies). Further restrictions imposed by the FDA will limit the amount of products a 503A pharmacy can ship out of state and their ability to ship sterile medications to clinics for in-office use.